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ABSTRACT
It has not been possible to determine the singular contribution of naive T lymphocytes to antigen-specific
immunity after hematopoietic stem cell transplantation (HSCT), because of the confounding effects of
donor-derived antigen-specific T lymphocytes present in most hematopoietic stem cell (HSC) products.
Because umbilical cord blood contains only naive T lymphocytes, we longitudinally evaluated the recipients of
unrelated cord blood transplantation (UCBT) for the presence of T lymphocytes with specificity for herpes-
viruses, to determine the contribution of the naive T lymphocytes to antigen-specific immune reconstitution
after HSCT. Antigen-specific T lymphocytes were detected early after UCBT (herpes simplex virus on day 29;
cytomegalovirus on day 44; varicella zoster virus on day 94). Overall, 66 of 153 UCBT recipients developed
antigen-specific T lymphocytes to 1 or more herpesviruses during the evaluation period. The likelihood of
developing antigen-specific T lymphocyte function was not associated with immunophenotypic T lymphocyte
reconstitution, transplant cell dose, primary disease, or acute and chronic graft-versus-host disease. These
results indicate that naive T lymphocytes present in the HSC inoculum can contribute to the generation of
antigen-specific T-lymphocyte immunity early after transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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SNTRODUCTION
Recipients of allogeneic hematopoietic stem cell
ransplantation (HSCT) are characterized by an immu-
odeﬁciency of varying severity and duration that can
redispose them to opportunistic infections and possibly
eoplastic relapse [1-3]. The T lymphocytes present in
he HSC inoculum are composed of both naive and
ntigen-speciﬁc T lymphocytes [4,5]. However, it has
ot been possible to determine the relative contributions
f donor-derived antigen-speciﬁc and naive T lympho-
ytes to antigen-speciﬁc immune reconstitution after
SCT. Because umbilical cord blood (UBC) does not
ontain antigen-speciﬁc memory T lymphocytes, unre-
ated cord blood transplantation (UCBT) represents a
nique clinical opportunity to determine the contribu- gion of naive T lymphocytes to posttransplantation an-
igen-speciﬁc immunity without the impact of donor-
erived antigen-speciﬁc T lymphocytes.
Consequently, we longitudinally evaluated UCBT
ecipients for their development of antigen-speciﬁc T
ymphocytes with speciﬁcity for a clinically relevant
roup of environmental pathogens, the herpesviruses,
o determine the contribution of naive T lymphocytes
o post-HSCT antigen-speciﬁc immunity.
ETHODS
tudy Population
The COBLT (Cord Blood Transplant) study
roup was a multi-institutional phase II trial of UCBT
1335
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G. Cohen et al.1336ponsored by the National Heart, Lung and Blood
nstitute of the National Institutes of Health. The
ransplantation protocol was approved by the institu-
ional review board of each participating institution.
ediatric patients (under age 18 years) with both ma-
ignant and nonmalignant diseases underwent trans-
lantation after receiving trial-designated preparative
egimes. Patients with neoplastic diseases, other than
hose diagnosed with infant leukemia, were condi-
ioned with total body irradiation (TBI) (9 fractions of
50 cGy) given twice a day on days 8 to 4; cyclo-
hosphamide 60 mg/kg on days 3 and 2; and
ntithymocyte globulin (ATG), equine, 15 mg/kg
wice a day on days 3 to 1, with methylpred-
isolone (MP) 1 mg/kg given before each dose. Pa-
ients diagnosed with infant leukemia received oral
usulfan 20-40 mg/m2/dose, with dosing based on
atient age with pharmakinetic dose adjustment, or
ntravenous busulfex 0.8-1.0 mg/kg, with dosing based
n patient age, for 16 doses on days 8 through 5,
nd melphalan 45 mg/m2 rather than TBI. Most pa-
ients with nonmalignant disease were prepared with
usulfan 1 mg/kg orally given every 6 hours for 16
oses on days 9 to 5; cyclophosphamide 50 mg/kg
n day 5 to 2, and ATG and MP on days 3 to
1. On the day of transplantation, patients received 2
oses of intravenous MP (1 mg/kg), with 1 dose given
ust before the infusion of the UBC unit. Graft-
ersus-host disease (GVHD) prophylaxis comprised
ntravenous MP, 0.5 mg/kg twice a day on days 1 to
4, followed by 1 mg/kg twice a day on days 5 to
19 or until the ﬁrst day that the absolute neutrophil
ount (ANC) reached 500/mm3, at which time the
ose was tapered at a rate of 0.2 mg/kg/week. Cyclo-
porine was begun on day 3 and was continued to at
east day 180, at which point the dose was tapered at
rate of 5% per week of the initial dose if the patient
xhibited no evidence of GVHD.
Each patient underwent transplantation with only 1
BC unit. Initial HLA typing was done by low/inter-
ediate molecular typing for HLA-A and HLA-B alleles
nd high-resolution molecular typing for HLA-DRB1.
nitial eligibility criteria required at least a 4 of 6
atch, or a 3 of 6 match if the match was based on
igh-resolution molecular typing for HLA-A and -B.
ost patients initially tested with low/intermediate
olecular typing were retrospectively retyped with
igh-resolution molecular typing for HLA-A and
LA-B alleles (ie, ﬁnal HLA typing). For analysis
urposes, the ﬁnal HLA typing was used.
Previous infection with herpesviruses (herpes sim-
lex virus [HSV], cytomegalovirus [CMV], and vari-
ella zoster virus [VZV]) was determined by standard
retransplantation serology of the recipients. Serology
as performed in the clinical laboratories of the par-
icipating transplantation centers according to institu-
ional procedures. All UBC units used for transplan- cation were negative for CMV IgM. Surveillance for
MV reactivation posttransplantation was done ac-
ording to institutional policy; CMV antibody–nega-
ive recipients received CMV-negative or leukocyte-
epleted blood products. CMV-positive recipients
ere permitted to receive prophylaxis with ganciclovir
fter day 100 once their ANC reached 750/mm3 for 2
ays according to institutional policy. HSV-positive
ecipients could receive prophylactic acyclovir. Pneu-
ocystis carinii and fungal prophylaxes and intravenous
mmunoglobulin administration were given according
o institutional practice.
Clinically signiﬁcant infections and their causative
rganisms were recorded, as were the causes of death.
ll data were retrospectively reviewed centrally for
ccuracy.
ssessment of Immune Reconstitution
Peripheral blood was collected in preservative-free
eparin from UCBT recipients at 1, 3, 6, 9, 12, 18, 24,
nd 36 months after transplantation. Specimens were
ransported overnight to the Children’s Hospital Los
ngeles for central evaluation of both immunopheno-
ype and antigen-speciﬁc T-lymphocyte proliferation.
hole blood specimens were analyzed for the per-
entages and absolute number of CD3-, CD4-, CD8-,
D19-, CD4-, CD45RA-, CD45RO-, and CD56-
xpressing leukocytes using 3-color immunoﬂuores-
ence and ﬂuorescent activated cell sorter analysis.
Mononuclear cells were isolated on discontinuous
radients (Ficoll 1.077). The interface cells were col-
ected, washed and suspended at 5  105 cells/mL in
PMI 1640 medium with 10% heat-activated human
 serum, glutamine, and antibodies. Then 1  105
ells (0.2 mL) were added to U-bottom microtiter
ells, and the optimal concentration of antigen was
dded. Lysates of HSV-, CMV-, and VZV-infected
broblasts were obtained from Dr. Myron Levin,
niversity of Colorado, Denver, CO. Tetanus toxoid
Aventis Pasteur, Swiftwater, PA) was used as a spec-
ﬁcity control in recipients. Assays were performed in
riplicate. Cultures were pulsed with tritiated thymi-
ine (1 Ci/well) on day 6. After 18 hours, cells from
he stimulated and control wells were harvested, and
he incorporated radioactivity was determined. In-
reases in counts per minute (CPM)  3000 (mean-
timulated cells minus mean-control cells) were con-
idered positive [6].
tatistical Considerations
Kaplan-Meier estimates of the cumulative inci-
ence of positive antigen-speciﬁc responses were cal-
ulated, with recipients who did not develop a positive
esponse censored at the time of their last negative
valuation. Differences between cumulative incidence
urves were tested by the log-rank test. Among recip-
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Antigen-Specific Immune Reconstitution 1337ents who developed positive antigen-speciﬁc re-
ponses, the times to ﬁrst positive response were com-
ared using nonparametric tests (Wilcoxon). All
alculations were done using SAS, release 8.2 (SAS
nstitute, Cary, NC).
ESULTS
tudy Population
The herpesvirus-speciﬁc T-lymphocyte prolifera-
ive responses of 153 recipients were determined on 1
r more occasions. Overall, 415 assays of T-lympho-
yte proliferation to the herpesviruses were per-
ormed. Forty-ﬁve recipients were tested once; 36
ecipients, twice; 26 recipients, three times, and
6 recipients, 4 or more times. Of the 153 recipients,
6 recipients had a positive proliferative response to 1
r more viruses, whereas 87 recipients had no detect-
ble responses to any virus over the 4 years of evalu-
tion (Table 1).
ntigen-Specific T-Lymphocyte Responses
HSV. Forty recipients developed a positive prolif-
rative response to HSV, with the ﬁrst positive re-
ponse detected on day 29 and the last conversion to a
ositive response occurring on day 1120. Twenty-ﬁve
ecipients developed a positive proliferative response
uring the ﬁrst 12 months after UCBT. Sixty-six
ecipients had serologic evidence of pretransplanta-
ion HSV infection (Table 1).
CMV. Thirty-two recipients developed a positive
roliferative response to CMV, with the ﬁrst positive
esponse detected on day 44 and the last conversion to
positive response occurring on day 1506. Thirteen
ecipients developed a proliferative response during
he ﬁrst 12 months after UCBT. Sixty recipients had
retransplantation serologic evidence of pretransplan-
ation CMV infection.
VZV. Fifty recipients developed a positive prolif-
rative response to VZV, with the ﬁrst positive re-
ponse detected on day 94 and the last conversion to a
ositive response occurring on day 1121. Twenty-one
ecipients developed a positive proliferative response
uring the ﬁrst 12 months after UCBT. Eighty recip-
ents were serologically positive for VZV before
ransplantation.
Overall, 28 recipients developed positive prolifer-
tive responses to only 1 herpesvirus, 20 recipients did
o to 2 viruses, and 18 recipients did so to all 3 viruses,
ndicating that their proliferative responses were an-
igen-speciﬁc (Table 2). Eighty-seven recipients did
ot develop detectable antigen-speciﬁc T-lymphocyte
roliferation to any of the 3 herpesviruses during the
valuation period. ampact of Infection on the Development of
ntigen-Specific Responses
Because the majority (84%) of evaluable recipients
ad serologic evidence of previous herpesvirus infec-
ion, we hypothesized that viral reactivation/infection
able 1. Characteristics of 153 UCBT Recipients Assessed for Anti-
erpesvirus T-lymphocyte Proliferative Responses
Antigen-Specific Response
Negative
(n  87)
Positive
(n  66)
All
(n  153)
atient-related
Age, years
Median 5.4 7.8 6.3
Range 0.4–17 0.6–17.9 0.4–17.9
ex, no. (%)
Male 48 (55) 46 (70) 94 (62)
Female 39 (45) 20 (30) 59 (38)
ansky score
< 80 15 (17) 9 (14) 24
> 80 72 (83) 57 (86) 139
isease-related
Primary disease, no. (%)
Malignant 79 (91) 58 (88) 137 (90)
Nonmalignant 8 (9) 8 (12) 16 (10)
nfection-related
Pretransplantation HSV
status, no. (%)
Negative 31 (47) 25 (45) 56 (46)
Positive 35 (53) 31 (55) 66 (54)
Pretransplantation CMV
status, no. (%)
Negative 32 (45) 37 (64) 69 (53)
Positive 39 (55) 21 (36) 60 (47)
Pretransplantation VZV
status, no. (%)
Negative 20 (34) 11 (21) 31 (28)
Positive 38 (66) 42 (79) 80 (72)
Pretransplantation CMV/
VZV/HSV status,
no. (%)
All negative 12 (17) 8 (14) 20 (16)
Positive for at least 1 virus 59 (83) 50 (86) 109 (84)
Posttransplantation viral
infection, no. (%)
Noninfected 53 (61) 31 (47) 84 (55)
Infected 34 (39) 35 (53) 69 (45)
ransplantation-related
HLA (final typing), no. (%)
< 4/6 59 (68) 34 (52) 93 (61)
> 5/6 28 (32) 32 (48) 60 (39)
Acute GVHD (reviewed
grade), no. (%)
< 1 54 (62) 39 (59) 93 (61)
> 2 33 (38) 27 (41) 60 (39)
Chronic GVHD, no. (%)
No 60 (69) 50 (76) 110 (72)
Yes 27 (31) 16 (24) 43 (28)
Cell dose, cells/kg  108
Median 6.5 6.2 6.3
Range 1.4–29.1 1.7–20.4 1.4–29.1fter UCBT was likely to be the initial antigenic
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G. Cohen et al.1338timulus for the development of antigen-speciﬁc T
ymphocytes in most recipients.
To determine the impact of clinical infection on
eveloping anti-herpesvirus T-lymphocyte responses,
e compared the time of detection of the ﬁrst positive
ntigenic-speciﬁc response to any virus in recipients
ho did and did not have clinically detected infections
Figure 1). There was no difference in the timing or
he frequency of development of antigen-speciﬁc T-
ymphocyte responses based on whether clinical infec-
ion had or had not occurred (P  .14; Wilcoxon’s
est). Thus, recipients without clinical infection (ie,
oninfected) were as likely to develop antigen-speciﬁc
-lymphocyte responses as recipients with any detect-
ble infection (ie, infected).
The impact of posttransplantation infection on the
evelopment of antigen-speciﬁc immunity to the in-
able 2. Speciﬁcity of Anti-herpesvirus T-lymphocyte Responses
Number of Antigens
with Positive Responses
Antigen
(no. of recipients positive)
HSV CMV VZV
1 7 5 16
2* 15 9 16
3 18 18 18
Total 40 32 50
HSV/CMV, 4; HSV/VZV, 11; CMV/VZV, 5.
igure 1. Time from transplantation to ﬁrst positive antigen re-
ponse for 31 patients with no recorded clinical viral infections and
5 patients with viral infections. No signiﬁcant difference is seenretween the 2 samples (P  .14; Wilcoxon’s test).ividual viruses was also determined (Figure 2). In-
reases in CPM of  3000 over background ( CPM)
ere considered positive. There was no association
etween the time of appearance or the frequency of
ositivity and clinical infection with any of the 3 her-
es viruses. Furthermore, recipients with detectable
MV antigenemia were not more likely to develop
ositive proliferative responses to CMV than were
igure 2. Impact of posttransplantation viral infection on the de-
elopment of anti-herpes T-lymphocyte responses. Results are the
rst positive response to the individual virus or the last negative
esponse: (A) HSV; (B) CMV; (C) VZV. A  CPM  3000 was
onsidered positive.ecipients without antigenemia (data not shown).
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Antigen-Specific Immune Reconstitution 1339mpact of a Positive Antigen-Specific
-Lymphocyte Response on Death
ue to Infection
Although clinical infection did not increase the
ikelihood of developing antigen-speciﬁc prolifera-
ion, the presence of an antigen-speciﬁc T-lympho-
yte response decreased the likelihood of recipients
ying from clinical infection. Eleven recipients who
id not have detectable antigen-speciﬁc T lympho-
ytes died due to infection, whereas only 1 recipient
ith a positive response died (P  .02). Among these
1 negative recipients, 4 recipients died of viral infec-
ion, 4 of fungal infection, 2 of bacterial infection, and
due to mycobacterium, whereas the single recipient
ho had antigen-speciﬁc function died of a viral (hu-
an herpesvirus-6) infection (Table 3).
The variables listed in Table 1 were analyzed for
heir association with the likelihood of developing an
ntigen-speciﬁc response to 1 or more herpes viruses.
able 3. Causes of Infectious Deaths in UCBT Recipients with and
ithout Antigen-speciﬁc T-lymphocyte Responses to Herpesviruses
Positive (n  1) Negative (n  11)
iral: Human herpesvirus-6 Viral
CMV (2)
Adenovirus
Epstein-Barr virus
Fungal
Aspergillus (2)
Candida (2)
Bacterial
Klebsiella
Pseudomonas aeruginosa
Other
Mycobacterium avium
intracellulare
igure 3. Cumulative incidence of antigen-speciﬁc T-lymphocyte
egative before transplantation. Results are censored at the last ne
C) VZV, .81.o signiﬁcant associations (P  .01) were found for
cute GVHD, chronic GVHD, HLA match, recipient
ge, total cell dose, CD34 cell dose/kg, or pretrans-
lantation remission status.
Because viral reactivation after UCBT could be an
ntigenic stimulus for the development of antigen-
peciﬁc T lymphocytes, we analyzed the impact of
retransplantation herpesvirus seropositivity on the
evelopment of antigen-speciﬁc responses after trans-
lantation (Figure 3). Seronegative recipients were as
ikely as seropositive recipients to develop positive
roliferative responses to all 3 herpesviruses. These
esults indicate that (1) many recipients who are sero-
ogically negative for herpesvirus infection before
CBT may have had previous infections, and (2)
ndetected viral infection/reactivation is a common
ource of antigenic stimulation after UCBT.
Analysis of the kinetics of immunophenotypic re-
onstitution after UCBT (CD3, CD4, CD8, and
D19) showed no association of any immunopheno-
ype with the development of antigen-speciﬁc T-lym-
hocyte responses (Figure 4).
ISCUSSION
In the present study, we found that 66 of 153
CBT recipients (43%) developed T lymphocytes
ith speciﬁcity for 1 or more herpesviruses during the
rst 4 years after UCBT, and that the ﬁrst antigen-
peciﬁc responses could be detected as early as 29–100
ays after UCBT, depending on the virus. Because
ord blood does not contain antigen-speciﬁc memory
lymphocytes, the antigen-speciﬁc T lymphocytes
etected during the ﬁrst 12 months after UCBT are
ost likely derived from the naive T lymphocytes
eration in UCBT recipients who were serologically positive and
evaluation. Log-rank test P values: (A) HSV, .59); (B) CMV, .86;prolif
gative
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G. Cohen et al.1340nfused at the time of transplantation. Thus, the naive
lymphocytes contained in the UCB inoculum were
apable of differentiating into antigen-speciﬁc T lym-
hocytes with speciﬁcity for environmental pathogens
ithin the ﬁrst 100 days after transplantation.
The presence of standard post-UCBT immuno-
uppression (cyclosporine and steroids) did not in-
erfere with the development of antigen-speciﬁc T
ymphocytes. The antigen-speciﬁc T lymphocytes
ere capable of normal interleukin (IL)-2 produc-
ion, because the addition of exogenous IL-2 did
ot elicit antigen-speciﬁc proliferation that was not
resent without the addition of IL-2 (R. Parkman,
npublished data). However, the presence of anti-
en-speciﬁc proliferation does not indicate the
resence of fully functional antigen-speciﬁc T lym-
hocytes. We and others have described defects in
-interferon production and cytotoxic T-lympho-
yte function in HSCT recipients of bone marrow
n whom antigen-speciﬁc T-lymphocyte prolifera-
ion was detected [7,8].
More than 40 years ago, it was established that
ewborn infants immunized with Salmonella ﬂagella
ntigen could produce speciﬁc antibody [9]. The pres-
nce of intrauterine viral infections can be detected by
he presence of speciﬁc IgM antibodies at birth [10].
nfants born of mothers infected with Plasmodium fal-
iparum malaria have antigen-speciﬁc T lymphocytes
etected in their cord blood due to transplacental
alaria antigens [11]. Therefore, it is not surprising
hat the naïve T lymphocytes present in UCB are
apable of generating antigen-speciﬁc T lymphocytes
ithin months of transplantation.
Recipients of T-cell–depleted HSCT do not have
etectable immunophenotypic T lymphocytes or pro-
iferative responses to mitogen stimulation until 3
igure 4. Absolute lymphocyte counts of recipients who did and did
iral antigens: (A) CD3; (B) CD4; (C) CD8; (D) CD19.onths after HSCT [12]. T lymphocytes derived crom the newly engrafted donor HSCs can contribute
o the generation of antigen-speciﬁc T lymphocytes
nce thymopoiesis is established. Thus, antigen-spe-
iﬁc T lymphocytes ﬁrst detected more than 1 year
fter transplantation may be derived from either the
aive T lymphocytes contained in the UBC innocu-
um or recent thymic emigrants. However, antigen-
peciﬁc T lymphocytes detected before 1 year after
ransplantation are derived predominantly from the
nfused naive T lymphocytes. Future studies should
nclude T cell excision circles and other analyses of
hymopoiesis to assess its impact on the development
f antigen-speciﬁc immunity.
To eliminate the possibility that the antigen-spe-
iﬁc T lymphocytes detected after transplantation
ere derived from antigen-speciﬁc T lymphocytes
ontained in the UBC unit secondary to in utero
xposure to herpesvirus antigens, we compared the
evelopment of CMV-speciﬁc T lymphocytes be-
ween recipients who had received UBC units from
others seropositive (IgG) for CMV and mothers
eronegative for CMV. We found no association be-
ween maternal CMV antibody status and the devel-
pment of CMV-speciﬁc T lymphocytes (data not
hown).
Non–cord blood HSC products (bone marrow,
obilized peripheral blood cells) contain both naive
nd mature antigen-speciﬁc T lymphocytes. Recipi-
nts of mobilized peripheral blood stem cells have
ntigen-speciﬁc T lymphocytes continuously present
fter transplantation [13]. Consequently, much recent
esearch has focused on the homeostatic expansion of
onor-derived antigen-speciﬁc T lymphocytes as a
ource of posttransplantation immunity [14,15]. The
resent results suggest that the naive T lymphocytes
elop antigen-speciﬁc T- lymphocyte responses to 1 or more herpesnot devontained in the HSC inoculum may make a greater
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Antigen-Specific Immune Reconstitution 1341ontribution to antigen-speciﬁc immunity early after
SCT than had previously been realized.
An antigen-speciﬁc T lymphocyte response re-
uires both a competent immune system and a stim-
lating antigen. In the present study, we chose to not
mmunize UCBT recipients with a neoantigen, but
ather to follow the development of antigen-speciﬁc
-lymphocyte immunity to the herpesviruses second-
ry to viral reactivation or a de novo infection [16].
ecause the time of viral reactivation/infection is un-
nown for most recipients, the lack of an antigen-
peciﬁc T-lymphocyte response at any particular time
ay be due to a lack of antigeneic stimulation rather
han to immunoincompetence. Most recipients re-
ponded to only 1 or 2 herpesviruses and not to teta-
us toxoid (TT), demonstrating the speciﬁcity and the
ack of breadth of their proliferative responses.
Future clinical studies of UCBT recipients should
nclude scheduled immunizations starting at the time
f transplantation with an antigen (ie, TT) to deter-
ine the kinetics of immune reconstitution. Sixteen
CBT recipients developed proliferative responses to
T 1 or more years after UCBT after routine post-
ransplantation reimmunization. A pilot study was un-
ertaken to evaluate the response of UCBT recipients
o TT immunization early (90 days) after transplan-
ation. Ten recipients were immunized, 1 of whom
eveloped an antigen-speciﬁc proliferative response.
Because antigen-speciﬁc T lymphocytes are present
n non–cord blood HSC products, recall antigens like
T or herpesvirus antigens cannot be used to evaluate
he de novo development of posttransplantation antigen-
peciﬁc T-lymphocyte function unless the donor is neg-
tive. Non–cord blood transplantation recipients should
e immunized at the time of transplantation with a
eoantigen, such as keyhole limpet hemocyanin (KLH),
o determine whether antigen-speciﬁc T-lymphocyte
mmunity can develop in the immediate posttransplan-
ation period [17].
The present study demonstrates that pretransplan-
ation serology underestimates the frequency of previous
erpesvirus infection. In fact, the earliest response to
SV after UCBT (day 29) was in a recipient who was
erologically negative for HSV. Because many of the
lgorithms used for the peritransplantation administra-
ion of prophylactic anti-herpesvirus drugs are based on
erologic assessments, some recipients who might bene-
t from peritransplantation prophylaxis may not be
reated because of false-negative serologic results
18,19]. The in vitro assessment of anti-herpes T-lym-
hocyte proliferation in serologically negative leukemic
atients has demonstrated a 10% incidence of positive
-lymphocyte proliferative response (R. Parkman, un-
ublished data). Presumably, the lack of detectable pre-
ransplantation antibody was due to the immunosup-
ressive effect of previous antileukemic therapy.Because cord blood contains only naive T lympho-
ytes, concerns have been raised that UCBT recipi-
nts might be at increased risk of opportunistic infec-
ions, particularly with viral and fungal organisms, to
hich antigen-speciﬁc T lymphocytes might be
resent in other HSC sources. The potential func-
ional immaturity of cord blood T lymphocytes also
ight contribute to the inability of UCBT recipients
o respond fully to opportunistic infections [20,21].
he present data demonstrate that the naive T lym-
hocytes present in UCB are capable of generating
lymphocytes with speciﬁcity for herpesviruses
ithin the ﬁrst 100 days after transplantation, which
ay contribute to a decreased incidence of infec-
ious deaths after transplantation. In addition,
CBT recipients who develop antigen-speciﬁc im-
unity have a decreased likelihood of acute leuke-
ic relapse (P  .0003) and improved relapse-free
urvival (P  .0001) [22].
It will be difﬁcult in non–cord blood transplanta-
ion settings to determine the singular contribution of
he naive T lymphocytes contained in the HSC inoc-
lum to posttransplantation immune reconstitution.
owever, after UCBT, naive T lymphocytes can de-
elop into antigen-speciﬁc T lymphocytes early after
ransplantation and may contribute to both a de-
reased likelihood of death due to infection and im-
roved overall survival.
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